AQR Capital Management
TEVA icon

AQR Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

AQR Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Buy
107,729
+32,511
+43% +$1.08M ﹤0.01% 2208
2026
Q1 		$2.27M Buy
75,218
+6,281
+9% +$202K ﹤0.01% 2264
2025
Q4 		$2.15M Buy
68,937
+24,742
+56% +$610K ﹤0.01% 2088
2025
Q3 		$893K Buy
44,195
+18,166
+70% +$319K ﹤0.01% 2502
2025
Q2 		$436K Buy
26,029
+2,074
+9% +$33.5K ﹤0.01% 2690
2025
Q1 		$368K Buy
23,955
+4,732
+25% +$84.5K ﹤0.01% 2594
2024
Q4 		$424K Buy
19,223
+1,646
+9% +$29.9K ﹤0.01% 2325
2024
Q3 		$317K Buy
17,577
+1,433
+9% +$25.1K ﹤0.01% 2368
2024
Q2 		$262K Buy
+16,144
New +$249K ﹤0.01% 2323
2015
Q1 		– Sell
-206,919
Closed -$11.9M – 2307
2014
Q4 		$11.9M Hold
206,919
– – 0.02% 610
2014
Q3 		$11.1M Buy
206,919
+103,108
+99% +$5.46M 0.03% 562
2014
Q2 		$5.44M Buy
+103,811
New +$5.31M 0.01% 866

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

AQR Capital Management's TEVA Position: Q2 2026 in Review

AQR Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 43% in Q2 2026, buying an estimated $1.08M and bringing the position to 107,729 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

AQR Capital Management first reported a position in TEVA in Q2 2014 and has held it in 12 quarters since. The position peaked at $11.9M in Q4 2014. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • AQR Capital Management held 107,729 shares of Teva Pharmaceuticals worth $3.65M as of Q2 2026.
  • AQR Capital Management bought 32,511 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
  • Teva Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2208 holding.
  • AQR Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
  • AQR Capital Management's Teva Pharmaceuticals position peaked at $11.9M in Q4 2014.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.